The global erythropoietin drugs market is prognosticated to demonstrate steady growth in coming years, as reported by Transparency Market Research (TMR). The competitive ecosystem features a highly consolidated environment, with vendors involved in different tactics to beat the rival players. Leading vendors in the global erythropoietin drugs market engage in several organic and inorganic growth strategies. Mergers and acquisitions are a popular initiative undertaken by vendors in order to gain momentum in the global market.
The improvement of distribution channels is expected to be focused on by vendors operating in the global erythropoietin drugs market. This is likely to encourage vendors to find more distributors in their supply chain system. This will further amplify competition among the market players.
Request For Covid19 Impact Analysis –
Research and development activities play a pivotal role in this industry, and market vendors are anticipated to engage in application-specific research. The segment of biosimilars is expected to offer rich growth opportunity to vendors, with increased number of clinical trials and approvals. Under-penetrated market will be the focus of established vendors and market entrants, with the aim of expansions/launches.
Key vendors in the global erythropoietin drugs market are Johnson & Johnson, Amgen Inc., Biocon Ltd., F. Hoffmann-La Roche Ltd., and Pfizer, Inc.
According to TMR’s predictions, the global erythropoietin drugs market is prognosticated to rise at a 7.5% CAGR over the forecast period from 2017 to 2025, and projected to be worth US$19.3 bn by the end of the forecast period.
Planning To Lay Down Future Strategy? Request Brochure Of Erythropoietin Drugs Market
Based on the geographical segmentation, the global erythropoietin drugs market is expected to be dominated by North America. The region boasts of fee waivers, favorable reimbursement policies, and approval associated with the product, propelling the North America market. On the basis of drugs class, Epotin alfa is anticipated to remain dominant over the forecast period. This could be attributed to the high prevalence of renal failures and cancer, as the drug is majorly used in these instances.
Rising Incidence of Anemia to Drive Erythropoietin Drugs Market
Substantial economic stresses are amplified by anemia and also affect the quality of life. AS reported by the Center for Disease Control and Prevention (CDC), some 5.5 million ambulatory care patients suffer from anemia due to a nutritional deficiency, while the second most prevalent cause is chronic disease. Although anemia is a common disease symptom, it remains undiagnosed and undertreated, particularly for patients with chronic renal diseases (CRD) that are not dialyzed. Approximately 20 million people in the U.S. have CKD, 2-4 million of which have anemia. Thus, an increasing number of anemia patients are driving the global market for erythropoietin.